Today's Date
Siplizumab in T1DM
(
DESIGNATE
)
ITN Protocol #:
ITN095AI
Branded Name:
DESIGNATE
Treatment Protocol #:
Therapeutic Area:
Type 1 Diabetes
Current Status:
Follow-up
Summary:
A T cell phenotype signature driven dose finding study with siplizumab in type 1 diabetes mellitus
Clinical Operations Associate Director
Clinical Operations Manager
ITN Biologist
ITN Clinical Trial Physician
Study Personnel:
